Quanterix Announces Landmark Study Demonstrating Dual GFAP/NfL Blood Test Approach for Personalized Multiple Sclerosis Monitoring

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
Quanterix Releases Financial Results for the Third Quarter of 2025
Quanterix To Report Third Quarter 2025 Financial Results on November 10, 2025
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
Quanterix Releases Financial Results for the Second Quarter of 2025
Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025
Quanterix Announces Cooperation Agreement with Kent Lake Capital
Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.